ADMA Biologics (ADMA) drew fresh attention after reporting third quarter 2026 results with higher sales and net income than a year earlier, while reaffirming at least US$530 million in full year 2026 revenue guidance.
Recent trading shows that ADMA Biologics shares have picked up momentum, with a 30 day share price return of 28.09% and a 90 day gain of 43.40%. However, the year to date move is still down 23.49% and the 1 year total shareholder return has slipped 11.28%, while the very large 5 year total shareholder return suggests long term holders have seen substantial compounding from earlier levels.
Scan beyond ADMA Biologics and see how other plasma and healthcare specialists are priced today by reviewing our hand picked 38 healthcare AI stocks alongside this earnings move.
Bulls see ADMA Biologics as a profitable plasma specialist still trading at a discount to its estimated worth. Bears focus on the uneven share track record. Which case do the current valuation markers lean toward?
Against a last close of $13.68 for ADMA Biologics, the analyst consensus Narrative on Simply Wall St anchors fair value at $17.75. This points to meaningful upside in that model and leans heavily on earnings power and cash returns to shareholders.
The focus on higher margin ASCENIV within a more competitive standard IG market is shifting ADMA Biologics toward a product mix that has already supported adjusted EBITDA growth of 24% year over year on essentially flat first quarter 2026 revenue. This points to ongoing earnings leverage if this mix trend continues.
See why 51 investors see ADMA Biologics as 23% undervalued.
Result: Fair Value of $17.75 (UNDERVALUED)
Still, the narrative around ADMA Biologics relies heavily on ASCENIV offsetting BIVIGAM pressure, while ongoing lawsuits and guidance cuts leave less room for execution missteps.
Find out about the key risks to this ADMA Biologics narrative.
Mixed views like these only matter if you test them against the numbers yourself and move before the story shifts again. Weigh both sides carefully with the 3 key rewards and 1 important warning sign.
If you stop at ADMA Biologics, you only see one piece of the puzzle. Broaden your watchlist with other focused ideas that fit your style.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com